Status:
COMPLETED
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
Lead Sponsor:
AstraZeneca
Conditions:
Renal Failure
Eligibility:
All Genders
50-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
Eligibility Criteria
Inclusion
- Male or female subjects with end-stage renal failure aged 50-80 years, who have received regular haemodialysis treatment for at least 3 months
Exclusion
- Subjects will have no underlying condition that is expected to limit survival to less than 1 year and is also unrelated to end-stage renal disease (ESRD). Subjects should not have received a statin therapy within the past 6 months
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
2776 Patients enrolled
Trial Details
Trial ID
NCT00240331
Start Date
January 1 2003
End Date
October 1 2008
Last Update
May 19 2011
Active Locations (239)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
St Leonards, New South Wales, Australia
2
Research Site
Herston, Queensland, Australia
3
Research Site
Bregenz, Austria
4
Research Site
Feldkirch-Tisis, Austria